Medical Developments International Ltd - Asset Resilience Ratio
Medical Developments International Ltd (MVP) has an Asset Resilience Ratio of 26.86% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check strategic asset allocation of Medical Developments International Ltd to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2003–2025)
This chart shows how Medical Developments International Ltd's Asset Resilience Ratio has changed over time. See net asset quality index of Medical Developments International Ltd to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Medical Developments International Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Medical Developments International Ltd stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$17.84 Million | 26.86% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$17.84 Million | 26.86% |
Asset Resilience Insights
- Very High Liquidity: Medical Developments International Ltd maintains exceptional liquid asset reserves at 26.86% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Medical Developments International Ltd Industry Peers by Asset Resilience Ratio
Compare Medical Developments International Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 11.69% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131 |
Drug Manufacturers - Specialty & Generic | 1.37% |
|
Bausch Health Companies Inc
TO:BHC |
Drug Manufacturers - Specialty & Generic | 4.97% |
|
Dezhan HealthCare Co Ltd
SHE:000813 |
Drug Manufacturers - Specialty & Generic | 0.15% |
|
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Hainan Haiyao Co Ltd
SHE:000566 |
Drug Manufacturers - Specialty & Generic | 3.27% |
|
Shanxi Zhendong Pharmaceutical
SHE:300158 |
Drug Manufacturers - Specialty & Generic | 10.74% |
Annual Asset Resilience Ratio for Medical Developments International Ltd (2003–2025)
The table below shows the annual Asset Resilience Ratio data for Medical Developments International Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-06-30 | 26.86% | AU$17.84 Million ≈ $12.62 Million |
AU$66.40 Million ≈ $46.98 Million |
+10.41pp |
| 2024-06-30 | 16.46% | AU$9.73 Million ≈ $6.89 Million |
AU$59.16 Million ≈ $41.86 Million |
-6.07pp |
| 2023-06-30 | 22.52% | AU$24.66 Million ≈ $17.45 Million |
AU$109.49 Million ≈ $77.47 Million |
+2.40pp |
| 2022-06-30 | 20.12% | AU$20.40 Million ≈ $14.43 Million |
AU$101.36 Million ≈ $71.72 Million |
-16.09pp |
| 2021-06-30 | 36.21% | AU$36.28 Million ≈ $25.67 Million |
AU$100.17 Million ≈ $70.88 Million |
+19.83pp |
| 2020-06-30 | 16.39% | AU$15.54 Million ≈ $11.00 Million |
AU$94.85 Million ≈ $67.11 Million |
-13.82pp |
| 2019-06-30 | 30.21% | AU$25.62 Million ≈ $18.13 Million |
AU$84.80 Million ≈ $60.00 Million |
+28.61pp |
| 2018-06-30 | 1.60% | AU$794.00K ≈ $561.81K |
AU$49.55 Million ≈ $35.06 Million |
-2.45pp |
| 2017-06-30 | 4.05% | AU$1.69 Million ≈ $1.20 Million |
AU$41.76 Million ≈ $29.55 Million |
+1.90pp |
| 2003-06-30 | 2.15% | AU$250.00K ≈ $176.89K |
AU$11.63 Million ≈ $8.23 Million |
-- |
About Medical Developments International Ltd
Medical Developments International Limited manufactures and distributes emergency medical solutions in Australia, Asia, Europe, the United States, and internationally. The company operates through Pain Management and Respiratory segments. It offers Penthrox, a trauma and emergency pain relief product for use in hospitals, emergency departments, ambulance services, sport medicines, and for analges… Read more